Alfons J. van den Eertwegh

917 citations

24 papers · 729 indexed · h-index 12

Immunology top 5%
- Immunotherapy and Immune Responses 7
Oncology top 10%
- Cancer Immunotherapy and Biomarkers 9
- CAR-T cell therapy research 4
- Peptidase Inhibition and Analysis 4
- Colorectal Cancer Treatments and Studies 3
Immunology and Allergy
Radiology, Nuclear Medicine and Imaging
- Radiopharmaceutical Chemistry and Applications 3
Cancer Research
Pulmonary and Respiratory Medicine
- Prostate Cancer Treatment and Research 8
- Renal cell carcinoma treatment 4

Co-authors: Eric Claassen E Claassen Janet E. Buhlmann David M. Calderhead R J Noelle H. Perry Fell Alejandro Aruffo W J Boersma
Cited by: Immunology Oncology Immunology and Allergy
Journals: The Journal of Experimental Medicine (1 paper)Journal of Clinical Oncology (12 papers)The Journal of Immunology (2 papers)
Partner nations: Netherlands United States France

In The Last Decade

Alfons J. van den Eertwegh

24 papers receiving 708 citations

Peers

Countries citing papers authored by Alfons J. van den Eertwegh

Since Specialization

Citations

This map shows the geographic impact of Alfons J. van den Eertwegh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfons J. van den Eertwegh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfons J. van den Eertwegh more than expected).

Fields of papers citing papers by Alfons J. van den Eertwegh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfons J. van den Eertwegh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfons J. van den Eertwegh. The network helps show where Alfons J. van den Eertwegh may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alfons J. van den Eertwegh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alfons J. van den Eertwegh Line = papers co-authored together Alfons J. van den Eertwegh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract 1136: Tumor uptake and biodistribution of⁸⁹Zirconium-labeled ipilimumab in patients with metastatic melanoma during ipilimumab treatment Tumor Biology ·Iris H.C. Miedema,Gerben J.C. Zwezerijnen,Guus AMS van Dongen,Daniëlle J. Vugts,Marc C. Huisman,Otto S. Hoekstra,Tanja D. de Gruijl,Henk M.W. Verheul,Catharina W. Menke,Alfons J. van den Eertwegh	2019	3
2	Abstract CT145: Repeated radium-223-chloride versus rhenium-188-HEDP in patients with metastatic castration-resistant prostate cancer: RaRe study Cancer Research ·Jessica C.L. Notohardjo,Esther W. Bouman-Wammes,Joyce M. van Dodewaard - de Jong,Haiko J. Bloemendal,Rogier Lange,Rob ter Heine,Henk M.W. Verheul,John M. de Klerk,Alfons J. van den Eertwegh	2019	2
3	Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy Clinical Cancer Research ·Annelies W. Turksma,Veerle M.H. Coupé,Marc C. Shamier,Kevin Lam,Vincent A. de Weger,Jeroen A.M. Beliën,Alfons J. van den Eertwegh,Gerrit A. Meijer,Chris J.L.M. Meijer,Erik Hooijberg	2015	44
4	Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302. Journal of Clinical Oncology ·Deborah Ricci,Weimin Li,Thomas W. Griffin,Michael Gormley,Erin D. Henitz,Charles J. Ryan,Johann S. de Bono,Gerhardt Attard,Alfons J. van den Eertwegh,Dirk Schrijvers,John J. Gullo,H. Suttmann,Joan Carles,J.M. Piulats Rodriguez,Robert J. Jones,Christopher J. Logothetis,Dana E. Rathkopf,Howard I. Scher,Eleni Efstathiou	2014	2
5	Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Charles G. Drake,Eugene D. Kwon,Karim Fizazi,Alberto Bossi,Alfons J. van den Eertwegh,Christopher J. Logothetis,Howard I. Scher,Tomasz M. Beer,Brent McHenry,David Liu,Winald R. Gerritsen	2014	13
6	Pre-operative intradermal administration of CpG-B ± GM-CSF in stage I-III melanoma patients arms the sentinel lymph node: evidence for reduced tumor spread Journal for ImmunoTherapy of Cancer ·Mari F.C.M. van den Hout,Bas D. Koster,Rik J. Scheper,Rieneke van de Ven,Berbel J.R. Sluijter,Barbara G. Molenkamp,Alfons J. van den Eertwegh,P.A. van Leeuwen,M. Petrousjka van den Tol,Tanja D. de Gruijl	2013	1
7	CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). Journal of Clinical Oncology ·Charles G. Drake,Howard I. Scher,Alberto Bossi,Alfons J. van den Eertwegh,Brent McHenry,Thomas Fitzmaurice,Jean-Marie Cuillerot,Kevin M. Chin,Paul Gagnier,Karim Fizazi,Winald R. Gerritsen	2012	2
8	Lymphoid and myeloid biomarkers for clinical outcome of combined immunotherapy with granulocyte-macrophage colony-stimulating factor-tranduced allogeneic prostate cancer cells (GVAX) and ipilimumab in castration-resistant prostate cancer patients. Journal of Clinical Oncology ·Alfons J. van den Eertwegh,Tanja D. de Gruijl,Saskia J. Santegoets,Anita G.M. Stam,Mary E. von Blomberg,Kristen Hege,Natalie Sacks,Karin Jooss,Israel Lowy,Winald R. Gerritsen	2012	1
9	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine Cancer Research ·Basav N. Hangalapura,Dinja Oosterhoff,Jan de Groot,Louis Boon,Thomas Tüting,Alfons J. van den Eertwegh,Winald R. Gerritsen,Victor W. van Beusechem,Alexander Pereboev,David T. Curiel,Rik J. Scheper,Tanja D. de Gruijl	2011	26
10	Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer Clinical Cancer Research ·Vincent A. de Weger,Annelies W. Turksma,Quirinus J.M. Voorham,Zelda Euler,Herman Bril,Alfons J. van den Eertwegh,Elisabeth Bloemena,Herbert M. Pinedo,Jan B. Vermorken,Harm van Tinteren,Gerrit A. Meijer,Erik Hooijberg	2011	54
11	Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer BMC Cancer ·Charlotte M. Huijts,Saskia J. Santegoets,Alfons J. van den Eertwegh,Laura S Pijpers,John B.A.G. Haanen,Tanja D. de Gruijl,Henk M.W. Verheul,Hans van Vliet	2011	23
12	Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib Journal of Clinical Oncology ·AAM van der Veldt,Martijn R. Meijerink,Alfons J. van den Eertwegh,John B.A.G. Haanen,E. Boven	2009	2
13	Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) Journal of Clinical Oncology ·W.R. Gerritsen,Alfons J. van den Eertwegh,Tanja D. de Gruijl,H. Pieter van den Berg,R.J. Scheper,Nathalie Sacks,Israel Lowy,Elizabeth Stankevich,K. Hege	2008	34
14	Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC) Journal of Clinical Oncology ·W.R. Gerritsen,Alfons J. van den Eertwegh,Tanja D. de Gruijl,Giuseppe Giaccone,R.J. Scheper,Nathalie Sacks,Tom Harding,Israel Lowy,Elizabeth Stankevich,K. Hege	2007	15
15	Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma Journal of Clinical Oncology ·Alfons J. van den Eertwegh,R. J. Lensen,R.J. Scheper,Giuseppe Giaccone,Chris J.L.M. Meijer,Hetty J. Bontkes,Tanja D. de Gruijl,Erik Hooijberg	2006	8
16	A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study Journal of Clinical Oncology ·Johannes Voortman,Egbert F. Smit,Bart C. Kuenen,H. M. Pinedo,C. van Groeningen,Alfons J. van den Eertwegh,Deas M Brouwer,Helgi van de Velde,Giuseppe Giaccone	2005	9
17	Suppression of rat cytomegalovirus replication by antibodies against gamma interferon Journal of Virology ·Bart L. Haagmans,Peter H. van der Meide,F S Stals,Alfons J. van den Eertwegh,E Claassen,C. A. Bruggeman,M. C. Horzinek,V. E. C. J. Schijns	1994	20
18	In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. The Journal of Experimental Medicine ·Alfons J. van den Eertwegh,Randolph J. Noelle,Michael Roy,David M. Shepherd,Alejandro Aruffo,J A Ledbetter,W J Boersma,Eric Claassen	1993	218
19	Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. The Journal of Immunology ·David M. Calderhead,Janet E. Buhlmann,Alfons J. van den Eertwegh,E Claassen,R J Noelle,H. Perry Fell	1993	171
20	In vivo kinetics and characterization of IFN-gamma-producing cells during a thymus-independent immune response The Journal of Immunology ·Alfons J. van den Eertwegh,M Fasbender,Marc M. Schellekens,A. van Oudenaren,W.J.A. Boersma,Eric Claassen	1991	32

About Alfons J. van den Eertwegh

Alfons J. van den Eertwegh is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 24 papers that have together received 729 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Prostate Cancer Treatment and Research (8 papers), Immunotherapy and Immune Responses (7 papers), Renal cell carcinoma treatment (4 papers), CAR-T cell therapy research (4 papers), Peptidase Inhibition and Analysis (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Immunology (545 citations), Oncology (257 citations) and Immunology and Allergy (35 citations). Alfons J. van den Eertwegh has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include Eric Claassen, E Claassen, Janet E. Buhlmann, David M. Calderhead, R J Noelle, H. Perry Fell, Alejandro Aruffo, W J Boersma, Michael Roy and J A Ledbetter. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact